Emerging Biopharma

Juri inks $210M T-cell engager deal with China biotech

Juri Biosciences is offering EpimAb up to $210 million biobucks for licensing rights to a T-cell engager designed to treat metastatic prostate cancer.

Gabrielle Masson May 27, 2025 6:00am

Nominations now open for Fierce Biotech's 2025 Fierce 15

May 20, 2025 7:30am

A sleek metallic pen tip creates a trail of pink and purple glitter blending technology with artistic expression

Stylus outlines next-gen gene editing mission with $85M in hand

May 13, 2025 7:00am

Space shuttle takes off on background of blue sky

Former Inhibikase CEO launches new biotech for Parkinson's asset

May 12, 2025 12:44pm

Tango dances away from preclinical work to extend cash runway

May 12, 2025 8:37am

abstract black agate background with golden veins fake painted artificial stone marble texture

Versant unveils new autoimmune biotech with $100M fundraise

Apr 24, 2025 8:00am

More News

Boehringer slots synthetic lethal program into oncology pipeline

Apr 23, 2025 7:45am

BioNTech backing powers DualityBio toward $200M Hong Kong IPO

Apr 7, 2025 8:21am

Harbour launches obesity biotech on mission to preserve muscle

Mar 12, 2025 8:15am

Flagship-backed AI firm aims for 'scientific superintelligence'

Mar 10, 2025 1:47pm

See more stories